142 related articles for article (PubMed ID: 16273764)
1. Circulating soluble CD28 in patients with Behçet's disease: relationship to clinical manifestations.
Hamzaoui K; Hamzaoui A; Bouajina L; Houman H
Clin Exp Rheumatol; 2005; 23(4 Suppl 38):S49-52. PubMed ID: 16273764
[TBL] [Abstract][Full Text] [Related]
2. The relationship between plasma homocysteine level and HLA-B51 in patients with Behcet's disease: a case-control study.
Shadmanfar S; Shahram F; Nadji A; Akhlaghi M; Faezi ST; Sadeghi-Abdollahi B; Faridar A; Madanchi N; Davatchi F
Int J Rheum Dis; 2014 May; 17(4):466-70. PubMed ID: 24428874
[TBL] [Abstract][Full Text] [Related]
3. Preferential activation of circulating CD8+ and gammadelta T cells in patients with active Behçet's disease and HLA-B51.
Yasuoka H; Yamaguchi Y; Mizuki N; Nishida T; Kawakami Y; Kuwana M
Clin Exp Rheumatol; 2008; 26(4 Suppl 50):S59-63. PubMed ID: 19026117
[TBL] [Abstract][Full Text] [Related]
4. Vitamin D modulates peripheral immunity in patients with Behçet's disease.
Hamzaoui K; Ben Dhifallah I; Karray E; Sassi FH; Hamzaoui A
Clin Exp Rheumatol; 2010; 28(4 Suppl 60):S50-7. PubMed ID: 20868571
[TBL] [Abstract][Full Text] [Related]
5. Serum soluble CD30 levels in Behçet's disease.
Düzgün N; Ayaslioglu E; Tutkak H
Clin Exp Rheumatol; 2004; 22(4 Suppl 34):S17-20. PubMed ID: 15515777
[TBL] [Abstract][Full Text] [Related]
6. Tc1/Tc2 ratio in the inflammatory process in patients with Behçet's disease.
Houman H; Hamzaoui A; Ben Ghorbal I; Khanfir MS; Feki M; Hamzaoui K
Mediators Inflamm; 2004 Aug; 13(4):247-53. PubMed ID: 15545055
[TBL] [Abstract][Full Text] [Related]
7. Serum IL-33 levels and skin mRNA expression in Behçet's disease.
Hamzaoui K; Kaabachi W; Fazaa B; Zakraoui L; Mili-Boussen I; Haj-Sassi F
Clin Exp Rheumatol; 2013; 31(3 Suppl 77):6-14. PubMed ID: 23464866
[TBL] [Abstract][Full Text] [Related]
8. Levels of soluble E-selectin in patients with active Behcet's disease.
Sari RA; Kiziltunç A; Taysi S; Akdemir S; Gündoğdu M
Clin Rheumatol; 2005 Feb; 24(1):55-9. PubMed ID: 15338451
[TBL] [Abstract][Full Text] [Related]
9. Increased production of circulating soluble co-stimulatory molecules CTLA-4, CD28 and CD80 in patients with rheumatoid arthritis.
Cao J; Zou L; Luo P; Chen P; Zhang L
Int Immunopharmacol; 2012 Dec; 14(4):585-92. PubMed ID: 22917707
[TBL] [Abstract][Full Text] [Related]
10. Synovial lymphoid neogenetic factors in Behçet's synovitis: do they play a role in self-limiting and subacute course of arthritis?
Pay S; Musabak U; Simsek I; Erdem H; Pekel A; Sengul A; Dinc A
Clin Exp Rheumatol; 2007; 25(4 Suppl 45):S21-6. PubMed ID: 17949547
[TBL] [Abstract][Full Text] [Related]
11. HLA-B51 subtypes in Turkish patients with Behçet's disease and their correlation with clinical manifestations.
Demirseren DD; Ceylan GG; Akoglu G; Emre S; Erten S; Arman A; Metin A
Genet Mol Res; 2014 Jul; 13(3):4788-96. PubMed ID: 25062414
[TBL] [Abstract][Full Text] [Related]
12. The comparison between Behçet's disease and spondyloarthritides: does Behçet's disease belong to the spondyloarthropathy complex?
Chang HK; Lee DH; Jung SM; Choi SJ; Kim JU; Choi YJ; Baek SK; Cheon KS; Cho EH; Won KS
J Korean Med Sci; 2002 Aug; 17(4):524-9. PubMed ID: 12172050
[TBL] [Abstract][Full Text] [Related]
13. Serum galectin-3 and galectin-3 binding protein levels in Behçet's disease and their association with disease activity.
Lee YJ; Kang SW; Song JK; Park JJ; Bae YD; Lee EY; Lee EB; Song YW
Clin Exp Rheumatol; 2007; 25(4 Suppl 45):S41-5. PubMed ID: 17949550
[TBL] [Abstract][Full Text] [Related]
14. Ovarian reserve alterations in premenopausal women with chronic inflammatory rheumatic diseases: impact of rheumatoid arthritis, Behçet's disease and spondyloarthritis on anti-Müllerian hormone levels.
Henes M; Froeschlin J; Taran FA; Brucker S; Rall KK; Xenitidis T; Igney-Oertel A; Lawrenz B; Henes JC
Rheumatology (Oxford); 2015 Sep; 54(9):1709-12. PubMed ID: 25957439
[TBL] [Abstract][Full Text] [Related]
15. HLA-B51 and its allelic types in association with Behçet's disease and recurrent aphthous stomatitis in Korea.
Chang HK; Kim JU; Cheon KS; Chung HR; Lee KW; Lee IH
Clin Exp Rheumatol; 2001; 19(5 Suppl 24):S31-5. PubMed ID: 11760395
[TBL] [Abstract][Full Text] [Related]
16. Levels of soluble Fas/APO-1 in patients with Behçet's disease.
Hamzaoui K; Hamzaoui A; Zakraoui L; Chabbou A
Mediators Inflamm; 1998; 7(2):111-4. PubMed ID: 9836498
[TBL] [Abstract][Full Text] [Related]
17. Plasma homocysteine level in patients with Behcet's disease with or without thrombosis.
Shahram F; Faridar A; Hamedani MG; Nadji A; Naderi N; Mojarad Shafiee N; Rasker JJ; Davatchi F
Arch Iran Med; 2010 Nov; 13(6):476-81. PubMed ID: 21039001
[TBL] [Abstract][Full Text] [Related]
18. Association of MICA polymorphism with HLA-B51 and disease severity in Korean patients with Behcet's disease.
Park SH; Park KS; Seo YI; Min DJ; Kim WU; Kim TG; Cho CS; Mok JW; Park KS; Kim HY
J Korean Med Sci; 2002 Jun; 17(3):366-70. PubMed ID: 12068141
[TBL] [Abstract][Full Text] [Related]
19. Phenotypic abnormalities of peripheral blood mononuclear cells in patients with Behçet's disease and association with HLA-B51 expression.
Sakly K; Lahmar R; Nefzi F; Hammami S; Harzallah O; Sakly N; Sakly W; Hassine M; Mahjoub S; Ghedira I; Feki S
Immunol Invest; 2014; 43(5):463-78. PubMed ID: 24661088
[TBL] [Abstract][Full Text] [Related]
20. Serum Interleukin-33 in Behcet's Disease: Its Relation to Disease Activity and Clinical Manifestations.
Fawzy RM; Said EA; Mohamed SM; Fouad NA; Akl EM
Egypt J Immunol; 2015 Jun; 22(2):1-8. PubMed ID: 28502139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
